EMCDDA Home
  • EN
Search

Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive substances

EMCDDA, Lisbon, February 2009

Publication type:

Risk assessments

Issue:

8

Summary:

This publication presents the findings of the formal risk assessment on BZP, produced in 2007 by the Scientific Committee of the EMCDDA, with participation of additional experts from the European Commission, Europol and the EMEA. The risk assessment report, which was submitted to the European Commission and the Council of the European Union on 31 May 2007, examines the health and social risks of the drug, as well as information on international trafficking and the involvement of organised crime. Furthermore, the report considers the potential implications for placing the drug under control in the EU. On the basis of this report — and on the initiative of the European Commission — on 3 March 2008, the Council decided that BZP is to be subject to control measures.

Download as pdf (1.1 MB):

English (en)

Table of contents

  • Risk assessment report of a new psychoactive substance: 1-benzylpiperazine (BZP)
  • Europol–EMCDDA joint report on BZP
  • Review of the pharmacotoxicological data on 1-benzylpiperazine (BZP)
  • Criminological and sociological evidence and public health risks

Pages:

91

Price:

free

ISBN/ISSN:

978-92-9168-345-1

DOI:

10.2810/44197

Catalogue number:

TDAK08008ENC

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00

More contact options >>

Page last updated: Tuesday, 06 October 2009